October 8, 2012 11:09 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report published Monday, Benchmark Company reiterated its Buy rating on RTI Biologics (NASDAQ: RTIX), and slightly raised its price target from $4.50 to $5.00.Benchmark Company noted, “We are increasing our price target to $5.00, from $4.50, to reflect our increasing comfort in RTI's 18-month growth outlook. We anticipate Management will provide expanding visibility to new MAPC and porcine dermis products that could offer upside to our medium term growth outlook. At minimum, we anticipate greater visibility to our robust earnings growth outlook. Relative to our 37% EPS growth forecast next year, we feel our $5.00 price target remains conservative at 17x EPS of $0.24, plus $0.90 per share in cash.”RTI Biologics closed on Friday at $4.54.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.